Intra-Cellular Therapies

ITCI

Biotech

Health Care

Pharma

Country

US

Industry

Health Care

Market Cap

Mid Cap

Num. Employees

561

IPO Date

Jan 31, 2014

Create Alert

ITCI

Country

US

Industry

Health Care

Biotech

Health Care

+1

Create Alert

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 561 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled bipolar depression studies, which evaluated the effects of CAPLYTA on depression in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study 404) and as adjunctive therapy with lithium or valproate (Study 402).